Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6‐hydroxydopamine model of Parkinson’s disease

The Rat Brain in Stereotaxic Coordinates

Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585

Microglia: a sensor for pathological events in the CNS

Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396

Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice

Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628

Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration

Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144

Corpse clearance defines the meaning of cell death

Savill, J., & Fadok, V. A. (2000) · Nature · doi:10.1038/35037722 · Cited by 1,572

Neuropathology of Parkinson's Disease

Forno, L. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,556

Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation.

Huynh, M.-L. N., Fadok, V., & Henson, P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci11638 · Cited by 1,333

Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation

Huynh, M.-L. N., Fadok, V. A., & Henson, P. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0211638 · Cited by 957

Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia

Kim, W., Mohney, R. P., Wilson, B. C., Jeohn, G., Liu, B., & Hong, J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06309.2000 · Cited by 881

Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease

Gao, H., Jiang, J., Wilson, B. C., Zhang, W., Hong, J., & Liu, B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00928.x · Cited by 690

The Role of Microglia and Astrocytes in the Pathomechanism of Neuroinflammation in Parkinson’s Disease—Focus on Alpha-Synuclein

Harackiewicz, O., & Grembecka, B. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2311203 · Cited by 39

Progressive changes of orexin system in a rat model of 6-hydroxydopamineinduced Parkinson’s disease

Cui, L., Li, B., Jin, X., Lin, Z., & Shi, J. (2010) · Neuroscience Bulletin · doi:10.1007/s12264-010-0410-9 · Cited by 34

α‐Synuclein induced cell death in mouse hippocampal (HT22) cells is mediated by nitric oxide‐dependent activation of caspase‐3

Adamczyk, A., Wilkaniec, A., Czapski, G. A., & Strosznajder, J. B. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.07.019 · Cited by 32

Microbiota, Tryptophan and Aryl Hydrocarbon Receptors as the Target Triad in Parkinson’s Disease—A Narrative Review

Iwaniak, P., Owe-Larsson, M., & Urbańska, E. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052915 · Cited by 34

Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease

Haque, A., Samantaray, S., Knaryan, V. H., Capone, M., Hossain, A., Matzelle, D. D., Chandran, R., Shields, D. C., Farrand, A. Q., Boger, H. A., et al. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113315 · Cited by 30

Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra

MacGillivray, L., Reynolds, K. B., Sickand, M., Rosebush, P. I., & Mazurek, M. F. (2011) · Synapse · doi:10.1002/syn.20954 · Cited by 32

2,5-Hexanedione induces dopaminergic neurodegeneration through integrin αMβ2/NADPH oxidase axis-mediated microglial activation

Zhang, C., Hou, L., Yang, J., Che, Y., Sun, F., Li, H., & Wang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0091-7 · Cited by 32

Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?

Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33

The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications

Kuter, K. Z., Cenci, M. A., & Carta, A. R. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.02.004 · Cited by 31

Strategic Selection of Neuroinflammatory Models in Parkinson's Disease: Evidence from Experimental Studies

More, S. V., Kumar, H., Kim, I., Koppula, S., Kim, B.-W., & Choi, D. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990059 · Cited by 31

Pinitol Prevents Lipopolysaccharide (LPS)-Induced Inflammatory Responses in BV2 Microglia Mediated by TREM2

Kong, J., Du, Z., & Li, D. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00187-z · Cited by 30

Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson’s disease

Воронин, М. В., Андреевич, К. И., Воронков, Д. Н., & Середенин, С. Б. (2019) · Scientific Reports · doi:10.1038/s41598-019-53413-w · Cited by 31

Patient-Derived Induced Pluripotent Stem Cell-Based Models in Parkinson’s Disease for Drug Identification

Kouroupi, G., Antoniou, N., Prodromidou, K., Taoufik, E., & Matsas, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197113 · Cited by 30

Role of dopamine in the recruitment of immune cells to the nigro-striatal dopaminergic structures

Espinosa‐Oliva, A. M., de Pablos, R. M., Soto, M. S., Villarán, R. F., Carrillo-Jiménez, A., Santiago, M., Venero, J. L., Herrera, A. J., Cano, J., & Machado, A. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.01.006 · Cited by 29

Exercise training upregulates CD55 to suppress complement-mediated synaptic phagocytosis in Parkinson’s disease

Yao, H., Tong, W., Song, Y., Li, R., Xiang, X., Cheng, W., Zhou, Y., He, Y., Yang, Y., Liu, Y., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03234-0 · Cited by 29

Daidzein exerts neuroprotective activity against MPTP‐induced Parkinson's disease in experimental mice and lipopolysaccharide‐induced BV2 microglial cells

Wu, Q., Wang, M., Chen, W., Wang, K., & Wang, Y. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22949 · Cited by 28

Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease: removing axonal debris

Moráles, I., Puertas‐Avendaño, R., Sánchez, A., Perez‐Barreto, A., Rodriguez‐Sabate, C., & Rodrı́guez, M. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00262-1 · Cited by 28

The Expression and Release of Hsp60 in 6-OHDA Induced In Vivo and In Vitro Models of Parkinson’s Disease

Feng, M. J., Zhang, L., Liu, Z., Zhou, P., & Lu, X. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1127-8 · Cited by 26

Erratum to: Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson’s disease

Cui, L., Li, B., Jin, X., Zhao, L., & Shi, J. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0043-8 · Cited by 26

Subthalamic nucleus deep brain stimulation induces sustained neurorestoration in the mesolimbic dopaminergic system in a Parkinson's disease model

Fauser, M., Ricken, M. A., Markert, F., Weis, N., Schmitt, O., Gimsa, J., Winter, C., Badstübner-Meeske, K., & Storch, A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105404 · Cited by 27

Enteric glial cell reactivity in colonic layers and mucosal modulation in a mouse model of Parkinson’s disease induced by 6-hydroxydopamine

Thomasi, B. B. D. M., Valdetaro, L., Ricciardi, M. C., Hayashide, L. D. S., Fernandes, A. C. M. N., Mussauer, A., da Silva, M. L., Faria‐Melibeu, A. D. C., Ribeiro, M. G. L., Coelho‐Aguiar, J. D. M., et al. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.06.013 · Cited by 25

Protective effects of evening primrose oil on behavioral activities, nigral microglia and histopathological changes in a rat model of rotenone-induced parkinsonism

Mohammad, H. M. F., El-Baz, A. A., Mahmoud, O. M., Khalil, S., Atta, R., & Imbaby, S. (2022) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2022.102206 · Cited by 24

The pesticide fipronil injected into the substantia nigra of male rats decreases striatal dopamine content: A neurochemical, immunohistochemical and behavioral study

Bharatiya, R., Bratzu, J., Lobina, C., Corda, G., Cocco, C., Deurwaerdère, P. D., Argiolas, A., Melis, M. R., & Sanna, F. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112562 · Cited by 23

Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease

Klusa, V. Z., Isajevs, S., Svirina, D., Pupure, J., Beitnere, U., Rumaks, J., Svirskis, Š., Jansone, B., Dzirkale, Z., Muceniece, R., et al. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11114465 · Cited by 22

Phagocytosis‐related NADPH oxidase 2 subunit gp91phox contributes to neurodegeneration after repeated systemic challenge with lipopolysaccharides

Shahraz, A., Wißfeld, J., Ginolhac, A., Mathews, M., Sinkkonen, L., & Neumann, H. (2020) · Glia · doi:10.1002/glia.23890 · Cited by 22

Subthalamic Deep Brain Stimulation Affects Plasma Corticosterone Concentration and Peripheral Immunity Changes in Rat Model of Parkinson’s Disease

Grembecka, B., Glac, W., Listowska, M., Jerzemowska, G., Plucińska, K., Majkutewicz, I., Badtke, P., & Wrona, D. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09934-7 · Cited by 21

Transplantation of Nurr1‐overexpressing neural stem cells and microglia for treating parkinsonian rats

Yuan, Q., Chen, X., Wang, W., Li, J., Wang, X., Tang, Z., Xu, J., Lin, H. Y., Yang, Z., Li, L., et al. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13149 · Cited by 21

Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats

Elson, J. L., Yates, A. G., & Pienaar, I. S. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1045-4 · Cited by 22

6‐Hydroxydopamine induces brain vascular endothelial inflammation

Fu, Q., Song, R., Yang, Z., Shan, Q., & Chen, W. (2017) · IUBMB Life · doi:10.1002/iub.1685 · Cited by 21

A time-course study of microglial activation and dopaminergic neuron loss in the substantia nigra of mice with paraquat-induced Parkinson's disease

Yang, H.-M., Wang, Y., Liu, C.-Y., Zhou, Y.-T., & Zhang, X. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113018 · Cited by 19

Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson’s Disease

Pišlar, A. H., Tratnjek, L., Glavan, G., Živin, M., & Kos, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00412 · Cited by 20

Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration.

Kim, J., Jang, S., Choi, M., Chung, S., Choe, Y., Choe, H. K., Son, G. H., Rhee, K., & Kim, K. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0201 · Cited by 20

Lipids Nutrients in Parkinson and Alzheimer’s Diseases: Cell Death and Cytoprotection

Nury, T., Lizard, G., & Véjux, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072501 · Cited by 21

Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinson’s disease: a Complete Review

Mehan, S., Kaur, G., Dudi, R., Rajput, M., & Kalra, S. (2017) · Open Journal of Parkinson s Disease and Treatment · doi:10.17352/ojpdt.000001 · Cited by 19

Inflammatory reaction regulated by microglia plays a role in atrazine-induced dopaminergic neuron degeneration in the substantia nigra

Zhang, B., Ma, K., & Li, B. (2015) · The Journal of Toxicological Sciences · doi:10.2131/jts.40.437 · Cited by 19

Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson’s disease

Ip, C. W., Beck, S., & Volkmann, J. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1444-y · Cited by 22

Dual Roles of Microglia in the Basal Ganglia in Parkinson’s Disease

Choudhury, M. E., Kigami, Y., & Tanaka, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083907 · Cited by 18

HCH6-1, an antagonist of formyl peptide receptor-1, exerts anti-neuroinflammatory and neuroprotective effects in cellular and animal models of Parkinson’s disease

Wang, H., Cheng, Y., Yeh, T., Liu, H.-F., Weng, Y.-H., Chen, R., Chen, Y., Lu, J., Hwang, T., Wei, K., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115524 · Cited by 18

Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease

Schlachetzki, J. C. M., Marxreiter, F., Regensburger, M., Kulinich, A. O., Winner, B., & Winkler, J. (2014) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-130371 · Cited by 19

Progressive loss of nigrostriatal dopaminergic neurons induced by inflammatory responses to fipronil

Park, J. H., Park, Y. S., & Koh, H. C. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.06.011 · Cited by 18

Mildronate and its Neuroregulatory Mechanisms: Targeting the Mitochondria, Neuroinflammation, and Protein Expression

Klusa, V. Z., Beitnere, U., Pupure, J., Isajevs, S., Rumaks, J., Svirskis, Š., Dzirkale, Z., & Kalvinsh, I. (2013) · Medicina · doi:10.3390/medicina49070047 · Cited by 18

Quantitative imaging of Cu, Fe, Mn and Zn in the L-DOPA-treated unilateral 6-hydroxydopamine Parkinson's disease mouse model by LA-ICP-MS

Sussulini, A., Matusch, A., Klietz, M., Bauer, A., Depboylu, C., & Becker, J. S. (2012) · Biomedical Spectroscopy and Imaging · doi:10.3233/bsi-2012-0011 · Cited by 17

Neurotoxicity to dopamine neurons after the serial exposure to alcohol and methamphetamine: Protection by COX-2 antagonism

Blaker, A. L., Rodriguez, E. A., & Yamamoto, B. K. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.028 · Cited by 18

Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in Rats

Soner, B. C., Açıkgöz, E., İnan, S. Y., Ayla, Ş., Şahin, A. S., & Öktem, G. (2021) · Parkinson s Disease · doi:10.1155/2021/5553480 · Cited by 17

The hypnotic bromovalerylurea ameliorates 6-hydroxydopamine-induced dopaminergic neuron loss while suppressing expression of interferon regulatory factors by microglia

Higaki, H., Choudhury, M. E., Kawamoto, C., Miyamoto, K., Islam, A., Ishii, Y., Miyanishi, K., Takeda, H., Seo, N., Sugimoto, K., et al. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.06.013 · Cited by 17

MicroRNAs Modulating Neuroinflammation in Parkinson's disease

Saadh, M. J., Muhammad, F. A., Singh, A., Mustafa, M. A., Zuhairi, R. A. H. A., Ghildiyal, P., Hashim, G. M., Alsaikhan, F., Khalilollah, S., & Akhavan‐Sigari, R. (2024) · Inflammation · doi:10.1007/s10753-024-02125-z · Cited by 16

Substantia Nigra Hyperechogenicity Reflects the Progression of Dopaminergic Neurodegeneration in 6-OHDA Rat Model of Parkinson’s Disease

Zhang, S., Tao, K., Wang, J., Duan, Y., Wang, B., & Liu, X. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00216 · Cited by 16

Intranasal AdipoRon Mitigated Anxiety and Depression-Like Behaviors in 6-OHDA-Induced Parkinson ’s Disease Rat Model: Going Beyond Motor Symptoms

Azizifar, N., Mohaddes, G., Keyhanmanesh, ‬., Athari, S. Z., Alimohammadi, S., & Farajdokht, F. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04223-8 · Cited by 17

The microglial P2Y6 receptor as a therapeutic target for neurodegenerative diseases

Dundee, J. M., & Brown, G. C. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00438-5 · Cited by 16

GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson’s disease animal models

Ha, T.-Y., Kim, J.-B., Kim, Y., Park, S. M., & Chang, K. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107432 · Cited by 14

Partial dopaminergic denervation-induced impairment in stimulus discrimination acquisition in parkinsonian rats: A model for early Parkinson's disease

Eagle, A. L., Olumolade, O., & Otani, H. (2014) · Neuroscience Research · doi:10.1016/j.neures.2014.11.002 · Cited by 14

Do Naturally Occurring Antioxidants Protect Against Neurodegeneration of the Dopaminergic System? A Systematic Revision in Animal Models of Parkinson's Disease

Costas‐Ferreira, C., & Faro, L. R. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210421092725 · Cited by 14

Experimental Models to Study Immune Dysfunction in the Pathogenesis of Parkinson’s Disease

Šaponjić, J., Mejı́as, R., Nikolovski, N., Dragić, M., Canak, A., Papoutsopoulou, S., Özdemir, Y., Fladmark, K. E., Ntavaroukas, P., Muluk, N. B., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084330 · Cited by 13

Type 2 diabetes microenvironment promotes the development of Parkinson’s disease by activating microglial cell inflammation

Zhang, B.-H., Song, C., Tang, X., Tian, M., Liu, Y.-Q., Yan, Z., Duan, R., & Liu, Y.-M. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1422746 · Cited by 13

Overexpression of apolipoprotein E4 increases kainic-acid-induced hippocampal neurodegeneration

Zhang, X., Mao, X., Zhang, H., Zheng, X., Pham, T. M., Adem, A., Winblad, B. G., Mix, E., & Zhu, J. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.024 · Cited by 13

Systemic administration of 6-OHDA to rhesus monkeys upregulates HLA-DR expression in brain microvasculature

Emborg, M. E., Joers, V. L., Dilley, K., & Vermilyea, S. (2014) · Journal of Inflammation Research · doi:10.2147/jir.s67285 · Cited by 13

The Mitochondrial Ribosome: A World of Opportunities for Mitochondrial Dysfunction Toward Parkinson's Disease

Gonçalves, A. M. R., Pereira-Santos, A. R., Esteves, A. R., Cardoso, S. M., & Empadinhas, N. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7997 · Cited by 13

Escitalopram moderately outperforms citalopram towards anti-neuroinflammation and neuroprotection in 6-hydroxydopamine-induced mouse model of Parkinson’s disease

Ovlyakulov, B., Hu, B., Kan, H.-Y., Guo, Q., Li, X., Fan, H.-H., Wu, H., Wang, J., Zhang, X., & Zhu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112715 · Cited by 11

Long-Term Impact of Diffuse Traumatic Brain Injury on Neuroinflammation and Catecholaminergic Signaling: Potential Relevance for Parkinson’s Disease Risk

Wee, I. C., Arulsamy, A., Corrigan, F., & Collins‐Praino, L. E. (2024) · Molecules · doi:10.3390/molecules29071470 · Cited by 10

Effects of triptolide on the expression of MHC II in microglia in kainic acid‑induced epilepsy

Sun, Z., Du, M., Lu, Y., & Chang-qian, Z. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8891 · Cited by 10

Co-Administration of Gagam-Sipjeondaebo-Tang and Ibuprofen Alleviates the Inflammatory Response in MPTP-Induced Parkinson’s Disease Mouse Model and RAW264.7 Macrophages

Won, S., Ko, J. H., Jeon, H., Park, S., & Kim, S. (2021) · Pathogens · doi:10.3390/pathogens10030268 · Cited by 9

HMGB1 Mediates Inflammation-Induced DMT1 Increase and Dopaminergic Neurodegeneration in the Early Stage of Parkinsonism

Liang, T., Yang, S.-X., Qian, C., Du, L., Qian, Z., Yung, W., & Ke, Y. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03668-2 · Cited by 9

Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA

Chan, H. H. N., Kumar, S. S., & Zhuo, L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.023 · Cited by 8

Subthalamic nucleus but not entopeduncular nucleus deep brain stimulation enhances neurogenesis in the SVZ-olfactory bulb system of Parkinsonian rats

Fauser, M., Payonk, J. P., Weber, H., Statz, M., Winter, C., Hadar, R., Appali, R., van Rienen, U., Brandt, M., & Storch, A. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1396780 · Cited by 6

Lasting Impact: Exploring the Brain Mechanisms that Link Traumatic Brain Injury to Parkinson’s Disease

Edwards, S., Corrigan, F., & Collins‐Praino, L. E. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04706-x · Cited by 8

Microglial Activation and Inflammatory Responses in Parkinson's Disease Models Are Attenuated by TRPM2 Depletion

Ferreira, A. F. F., Feng, Z., Sun, H., & Britto, L. R. (2025) · Glia · doi:10.1002/glia.70055 · Cited by 7

Endogenous protection against the 6-OHDA model of Parkinson's disease in the Amazonian rodent Proechimys

Marques, M., Real, C. C., Victorino, D. B., Britto, L. R., Cavalheiro, É. A., Scorza, F. A., Ferraz, H. B., & Scorza, C. A. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134381 · Cited by 6

Evaluation of microglia in a rodent model of Parkinson’s disease primed with L-DOPA after sub-anesthetic ketamine treatment

Pottenger, A. E., Bartlett, M. J., Sherman, S. J., Falk, T., & Morrison, H. W. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136251 · Cited by 6

Lesion-associated microglia and macrophages mediate corralling and react with massive phagocytosis for debris clearance and wound healing after LPS-induced dopaminergic depletion

Heman-Bozadas, P., Romero, C., Martínez-Remedios, P., Freitag-Berenguel, I., Frías, A., Saavedra-López, E., Casanova, P. V., Roig-Martínez, M., Cribaro, G. P., Rovirosa-Hernández, M. D. J., et al. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.577874 · Cited by 6

Disease mechanisms as subtypes: Lysosomal dysfunction in the endolysosomal Parkinson's disease subtype

Mamais, A., Wallings, R. L., & Rocha, E. M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00009-6 · Cited by 6

Neuroinflammation in Alzheimer's, Parkinson's and Huntington's Diseases

Sastre, M., Katsouri, L., Birch, A. M., Renziehausen, A., Dexter, D. T., Crichton, R. R., & Ward, R. J. (2014) · Wiley eBooks · doi:10.1002/9781118406557.ch6 · Cited by 6

Role of Microglial Dysfunction in Parkinson’s Disease: From Multifactorial Causes to Neurodegeneration

Xu, Y., Han, T., Wu, Y., Liu, H., Hou, K., An, Z., Li, Y., Zhu, C., Wang, S., & Wei, J. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01505-1 · Cited by 5

Microglia Activation in the Midbrain of the Human Neonate: The Effect of Perinatal Hypoxic-Ischemic Injury

Panayotacopoulou, M. T., Papageorgiou, I. E., Pagida, M. A., Katsogridaki, A. E., Chrysanthou‐Piterou, M., Valous, N. A., Halama, N., Patsouris, E., & Konstantinidou, A. E. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab135 · Cited by 5

Diagnostics, rehabilitation and models of Parkinson’s disease

Dushanova, J. (2012) · Health · doi:10.4236/health.2012.431178 · Cited by 4

Aging, rather than Parkinson's disease, affects the responsiveness of PBMCs to the immunosuppression of bone marrow mesenchymal stem cells

Guan, Y., Zhao, C., Zou, H., Yan, X., Luo, L., Wu, J., Li, X., & Zhang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9670 · Cited by 4

Subthalamic nucleus deep brain stimulation does not alter growth factor expression in a rat model of stable dopaminergic deficiency

Statz, M., Schleuter, F., Weber, H., Kober, M., Plocksties, F. V., Timmermann, D., Storch, A., & Fauser, M. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137459 · Cited by 4

Causal association between atopic dermatitis and Parkinson's disease: A bidirectional Mendelian randomization study

Zhou, T., Wei, B., Hu, Y., Zhou, X., Cai, X., & Shi, X. (2024) · Brain and Behavior · doi:10.1002/brb3.3468 · Cited by 3

The Role of the Neuropeptide Substance P in the Pathogenesis of Parkinson’s Disease

Thornton, E., & Vink, R. (2012) · InTech eBooks · doi:10.5772/16987 · Cited by 4

Minocycline Alleviates Cluster Formation of Activated Microglia and Age-dependent Dopaminergic Cell Death in the Substantia Nigra of Zitter Mutant Rat

Taguchi, D., Ehara, A., Kadowaki, T., Sakakibara, S., Nakadate, K., Hirata, K., & Ueda, S. (2020) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.20-00022 · Cited by 3

Three-Dimensional Electron Microscopy Reconstruction of Degenerative Dopaminergic Neurons Surrounded by Activated Microglia in Substantia Nigra

Nakadate, K., & Tanaka‐Nakadate, S. (2015) · Ultrastructural Pathology · doi:10.3109/01913123.2015.1042609 · Cited by 3

Proinflammatory Chemical Signaling: Cytokines

Nagamoto‐Combs, K., & Combs, C. K. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_6 · Cited by 2

Alpha-synuclein and neuroinflammation in Parkinson's disease

Varanita, T., & Bubacco, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815950-7.00027-8 · Cited by 2

MHCII reduction is insufficient to protect mice from alpha-synuclein-induced degeneration and the Parkinson’s HLA locus exhibits epigenetic regulation

Kline, E. M., Jernigan, J. E., Scharer, C. D., Maurer, J., Hicks, S. L., Herrick, M. K., Wallings, R. L., Kelly, S. D., Chang, J., Menees, K. B., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-95679-3 · Cited by 1

Parkinson's disease: A chronic systemic inflammatory disorder

Khan, H., & Benskey, M. J. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00006-3 · Cited by 1

MPP+ disorders Irg1-Itaconate axis to promote M1 polarization of microglia by activating succinate dehydrogenase

Wang, L., Tang, Y.-Y., Zou, W., Zhang, P., Tang, X., & Zhang, P. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11191-x · Cited by 1

Chrysin loaded γ-cyclodextrin pullulan fast dissolving nanofibers for sublingual delivery in mitigating oxidative stress and managing depression

Saini, S., Pathak, T., Medda, N., Rani, S., Chaudhary, P., Singh, K., Ghosh, C., Prasad, R., Gupta, S., & Roy, P. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108242 · Cited by 1

Parkinson’s Disease: Involvement of Iron and Oxidative Stress

Dexter, D. T. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735896-00058 · Cited by 1

Role of Microglia in Parkinson’s Disease Pathology

Ciolac, D., & González‐Escamilla, G. (2024) · Neuromethods · doi:10.1007/978-1-0716-4083-8_4 · Cited by 1

Papel dos receptores purinérgicos em modelo animal de doença de Parkinson

Oliveira‐Giacomelli, Á. (2018) · doi:10.11606/t.46.2018.tde-26112018-074709 · Cited by 1

Avaliação do efeito do éster fenetil do ácido cafeico (CAPE) em modelos experimentais da Doença de Parkinson

Silva, R. D. B. (2014) · doi:10.11606/t.60.2014.tde-31102014-105854

CDNF in an experimental model of Parkinson's disease: studies on gene therapy and protein infusion

Bäck, S. (2014) · Työväentutkimus Vuosikirja

Role of cytokines in experimental neurodegenerative and neuroinflammatory disorders

Zhang, X. (2010) · Figshare

Involvement of CRH Receptors in the Neuroprotective Action of R-Apomorphine in the Striatal 6-OHDA Rat Model

Varçin, M., Bentea, E., Roosens, S., Michotte, Y. M., & Sarre, S. (2013) · Neuroscience & Medicine · doi:10.4236/nm.2013.44044

Gene therapy using synthetic microRNA directed against GAD67 has beneficial effect on motor behaviour in 6-OHDA lesioned rats

Wettergren, E. E., Quintino, L., & Lundberg, C. (2014) · Journal of Gene Therapy Aspects · doi:10.7243/2057-164x-1-1

Efeitos do exercício físico no modelo da doença de Parkinson em ratos.

Real, C. C. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2013.tde-20092013-110340

Parkinson’s Disease and the Immune System

Roberta, J., Crichton, R. R., & Dexter, D. T. (2012) · InTech eBooks · doi:10.5772/16868

New insights to the brain functions of prolyl oligopeptidase

Peltonen, I. (2012) · Työväentutkimus Vuosikirja

Brazil needs a national debate on bioprospecting.

Zani, C. L. (1999) · PubMed

O papel da microglia no modelo da doença de Parkinson induzido pela 6-hidroxidopamina.

Pereira, C. P. M. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2019.tde-18092019-145844

New insights underlying the early events of dopaminergic dysfunction in Parkinson’s DiseasePreprint

Cruz, H. L. D., Cruz, E. L. D., Zurhellen, C., York, H. T., Baun, J. A., Cruz, J. L. D., & Cruz, J. S. D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.27.313957

Kinetics of Microglial Activation and Degeneration of Dopamine-Containing Neurons in a Rat Model of Parkinson Disease Induced by 6-Hydroxydopamine

Henry, V., Paillé, V., Lelan, F., Brachet, P., & Damier, P. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181b767b4 · Cited by 34

Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease

Virgone‐Carlotta, A., Uhlrich, J., Akram, M. N., Ressnikoff, D., Chrétien, F., Domenget, C., Gherardi, R. K., Despars, G., Jurdic, P., Honnorat, J., et al. (2013) · Glia · doi:10.1002/glia.22546 · Cited by 52

Analyses of microglia activation associated to degenerative dopamine containing neurons induced by 6-OHDA on rats. Implication on pathogenesis comprehension of Parkinson's disease

HENRY, V., & Damier, P. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)

A time-course study of microglial activation and dopaminergic neuron loss in the substantia nigra of mice with paraquat-induced Parkinson's disease

Yang, H.-M., Wang, Y., Liu, C.-Y., Zhou, Y.-T., & Zhang, X. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113018 · Cited by 19

Differential Effects of LPS and 6-OHDA on Microglia’s Morphology in Rats: Implications for Inflammatory Model of Parkinson’s Disease

Parra, I., Martínez, I., Ramirez‐Garcia, G., Tizabi, Y., & Mendieta, L. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00104-z · Cited by 34